NCT01353222 · MORE INFO

Limitations, agreements, and source contact

DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma · Source last updated 2017-05-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentation relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Complete source fields

certain Agreement

other Details: The results of the Study will be published and/or presented in an integrated manner reflecting the results observed across all participating centers. Accordingly, decisions on timing and content of publications and presentation relating to the Study will be coordinated by Dendreon in communication with institutions contributing patients to the Study.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice